The group�s principle activity is to integrate modern molecular, genomic, biophysical, and diagnostic techniques with animal models of Central Nervous System disease in order to discover new compounds for the treatment of a variety of neurological disorders. The group also provides solutions for Central Nervous System disorders and diseases affecting attention, learning, and memory including Alzheimer's disease. The group operates from United States.
